News

The current study consists of the two dose groups that provided the best results in the previous trial, with a control group and a 12-weeks treatment period. The

The endpoints of the out-patient, dose-ranging Phase II study were to determine the optimal dose of Ty800 for further development based on the safety, reactogenicity, and immunogenicity of

Additionally, Ranexa has significantly improved all measures of exercise performance compared to placebo, including reductions in the time to onset of angina (p=0.002) and time to the onset

The technology was discovered and patented by the Pharmaceutical Research Institute of Warsaw Poland and involves compounds that appear to be novel antimicrotubule agents. Donald Picker, president and

Under terms of this new agreement, Breckenridge will submit an abbreviated new drug application (ANDA) to the FDA for the product which will be developed by Helm. The

The study (DUAAL study) was a randomized, double-blind, multi-country study comparing Lipitor (n=103), Norvasc (amlodipine besylate) (n=104) and a combination of the two (n=104) in patients with coronary

Pursuant to the terms of the agreement, SciGen will seek governmental approvals for the sale of Generex Oral-lyn in the territory using SciGen’s own recombinant human insulin product.

The findings demonstrated equivalence between the 0.18% formulation and company’s 0.09% formulation of Xibrom given once daily in achieving the primary efficacy endpoint of absence of ocular inflammation

The acquisition includes the Empower line of contrast injector delivery systems, IRiS contrast management system and the EZ Chem point-of-care device, a unique chemistry device for testing serum